UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

FORM 8-K

___________________________

Current Report

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~July 126, 2026

___________________________

TRAVERE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

___________________________

Delaware

001-36257

27-4842691

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

3611 Valley Centre Drive, Suite 300

San Diego, CA 92130

(Address of Principal Executive Offices, including Zip Code)

(888) 969-7879

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

TVTX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~On June 12, 2026, William Rote, Ph~~5.~~D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027~~ 02(~~the “Retirement Date”~~b)~~, the 10 year anniversary of his employment with the Company.~~

ItOn isJuly ~~expected~~6, ~~that~~2026, ~~Dr.~~Sandra ~~Rote~~Calvin, ~~will~~chief ~~continue~~accounting toofficer ~~serve~~(CAO) inand ~~his~~principal ~~current~~accounting ~~position~~officer ~~through~~(PAO) of the ~~Retirement~~Company, ~~Date~~provided ~~and~~notice ~~will~~to ~~assist~~the inCompany of her intention to retire from employment with the ~~transition~~Company offollowing ~~his~~the ~~responsibilities.~~filing ~~The~~of ~~responsibilities~~the ~~currently~~Company’s ~~overseen~~Annual byReport ~~Dr.~~on ~~Rote~~Form ~~are~~10-K expected toin beFebruary ~~assumed~~2027 by(the ~~Jula~~“Retirement ~~Inrig~~Date”). The Company expects John Torell, ~~M.D.~~CFA, CPA, the Company's ~~Chief~~Vice ~~Medical~~President, ~~Officer~~Controller, to succeed Ms. ~~Effective~~ ~~July~~Calvin 1,as ~~2026,~~CAO Drand PAO. ~~Inrig~~The Board of Directors is ~~being~~expected ~~named~~to ~~Executive~~appoint ~~Vice~~Mr. ~~President,~~Torell ~~Head~~to those roles in advance of ~~Research~~the &Retirement ~~Development~~Date ~~and~~to ~~Chief~~facilitate ~~Medical~~an ~~Officer~~orderly transition of responsibilities.

~~The~~Since joining the Company ~~expects~~in to2021, ~~enter~~Mr. ~~into~~Torell, ahas ~~consulting~~been ~~arrangement~~responsible ~~with~~for Draccounting operations, financial reporting, SEC reporting, technical accounting, and internal controls over financial reporting and has served as Vice President, Controller since 2023. ~~Rote~~From 1997 to ~~enable~~2019, ~~continued~~Mr. ~~access~~Torell toheld Drpositions of increasing responsibility within the finance organizations at Pacific Life Insurance Company, including serving as Vice President, Controller; Vice President, Assistant Controller; and Vice President of Finance, Investment Management Division. ~~Rote~~Earlier ~~following~~in his ~~retirement~~career he was an Audit Manager with Deloitte. Mr. Torell is a Chartered Financial Analyst, a Certified Public Accountant and holds a B.A. in Economics-Business from the University of California, Los Angeles.

Forward-Looking Statements

This report contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements and expectations regarding the planned retirement of DrMs. ~~Rote~~Calvin, ~~and~~ the ~~planned~~transition ~~changes~~plan tofor ~~Dr.~~the ~~Inrig’s~~CAO/PAO ~~title and responsibilities~~role, and the ~~expected~~ timing thereof~~; and the expectation to enter into a consulting agreement with Dr~~. ~~Rote.~~ Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks related to human capital and the Company’s business needs and resources. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRAVERE THERAPEUTICS, INC.

Dated: June 16, 2026

By:

/s/ Eric Dube

Dated: July 9, 2026

By:

/s/ Eric Dube

Name:

Eric Dube

Title:

Chief Executive Officer

Filing Compare · Travere Therapeutics, Inc.